Annual zoledronic acid infusion lowers risk of fracture, death

Abstract

Patients with a prior hip fracture have 2.5 times the risk of a new fracture compared to age-matched persons without a previous hip fracture. For patients with a recent hip fracture, intravenous zoledronic acid annually is an option for reducing the risk of new fractures and death. Strength of recommendation (SOR) B: based on one well- designed randomized controlled trial.